KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...

Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...

The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized ...

Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.

Adverse Events There were 42 IVIG infusions. No serious AEs were observed and most of subjects tolerated the treatment protocol well. Table 2 summarizes the frequency of non-serious adverse ...

This latter effect is important both because therapy in CIDP is usually episodic and because IVIg is typically a more expensive treatment and indefinite monthly infusions would be quite resource ...